In conclusion, by employing a network-guided framework from discovery to experimental validation, this work not only delivers a validated pharmacodynamic signature for MMP12 inhibition and confirms its potent anti-tumor phenotypes but also identifies an ADAM9-driven adaptive response as a putative central determinant of therapeutic durability that awaits further testing. The gene discussed is ADAM9; the disease is neoplasm.